High and unsustainable cost of controlling the dengue vector aedes aegypti in the peruvian amazon

Objectives Vector control is the method of prevention and control of dengue outbreaks used in Peru. With the objective of calculating the costs incurred in vector control, an estimation of the costs of Aedes aegypti control of the Regional Health Directorate of Loreto, during the execution of the regional plan for surveillance and control of A. aegypti was carried out. Materials and methods Documentation was reviewed, and interviews were conducted with stakeholders about the costs of A. aegypti control interventions in its adult and larval stages, during 2017 and 2018. Results It was found that the costs incurred in the control of the dengue vector in the Loreto Region in the two years studied amount to: 3,807,858 and 4,066,380 soles during 2017 and 2018 respectively, 1’175,264 and 1’1210,232 dollars at the exchange rate of 2017 and 2018, however, the effect of the control activities is short-lived. Conclusions The high cost involved in vector control with the methods currently used and the short duration of its effect makes it unsustainable so studies should be conducted to find other more efficient methods of dengue control. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement This study did not receive any funding ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All data produced in the present work are contained in the manuscript